MCMi-Ra Choi

Mi-Ra Choi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Mi-Ra Choi has a total of 39 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Computational Design and Glycoengineering of Interferon‐Lambda for Nasal Prophylaxis Against Respiratory Viruses

    by Jeongwon Yun, Seungju Yang, Jae Hyuk Kwon, Luiz Felipe Vecchietti, Ji Hyun Choi, Mi‐Ra Choi, Keun Bon Ku, Hyun‐Joo Ro, Kyun‐Do Kim, Meeyoung Cha, et al.

    Interferon‐λ (IFN‐λ), a type III interferon that selectively targets epithelial cells, holds strong potential as an intranasal antiviral due to its ability to suppress respiratory virus replication without inducing systemic inflammation. However, clinical translation of human IFN‐λ3 (hIFN‐λ3) is hindered by limited thermostability, protease susceptibility, and rapid mucosal clearance. In this study, instability‐prone elements in hIFN‐λ3 are eliminated through artificial intelligence (AI)‐based backbone remodeling and targeted surface hydrophobic patch engineering. A protease‐sensitive loop is replaced with a de novo α‐helix, which shields neighboring hydrophobic patches and forms a new hydrophobic core, yielding an engineered variant (hIFN‐λ3‐DE1) with enhanced thermostability (Tm > 90 °C), protease resistance, and preserved antiviral activity and structural integrity even after extended heat stress (two weeks at 50 °C). Further glyco‐engineering introduces an N‐linked glycan at a site distant from receptor‐binding interfaces, improving solubility, production yield, and diffusion through synthetic nasal mucus. Intranasal administration of the resulting variant (G‐hIFN‐λ3‐DE1) enables effective mucosal penetration and provides a more rapid onset of in vivo prophylactic protection against influenza A virus. These findings highlight a robust and versatile strategy that combines AI‐driven structural design with glyco‐engineering to develop scalable, bioavailable, and functionally enhanced nasal biologics for respiratory virus prophylaxis.


  • Therapeutic Effect of Extended Uvulopalatal Flap Surgery in Patients With Obstructive Sleep Apnea

    by Jae-Yoon Kang, Se Yeon Im, Han Wool John Sung, Mi-Ra Choi, Soo Kyoung Park, Yong Min Kim

    Background and Objective Although numerous studies have reported surgical results of uvulopalatopharyngoplasty, efficacies of extended uvulopalatal flap (EUPF) surgery have only been reported in a few studies. Thus, the aim of this study was to evaluate the success rate of EUPF and investigate the advantage and practicality of this surgery.Methods Medical records of patients who underwent EUPF surgery were retrospectively analyzed. Through medical record analysis, demographic information was confirmed. Postoperative polysomnography (PSG) results were divided into a surgical ‘success’ group and a ‘failure’ group. Patients’ PSG results, questionnaires, and cephalometry were comparatively analyzed.Results All sleep parameters of PSG except rapid eye movement latency and hypopnea index were significantly improved after surgery. Ten patients were in the success group (success rate, 33.3%) and 20 patients were in the failure group. Among preoperative PSG parameters, apnea-hypopnea index, apnea index, and number of awakenings showed significant differences between the two groups. However, there were no significant differences in results of cephalometry or Friedman stage between the two groups.Conclusions The EUPF surgery can change sleep factors and improve subjective symptoms in obstructive sleep apnea patients. It could be considered as one of the treatment options for patients with surgical indications, although its success rate was only 33.3%.

  • Open Access

    Potential Role of Cytosolic RNA Sensor MDA5 as an Inhibitor for Keratinocyte Differentiation in the Pathogenesis of Psoriasis

    by Dong-Kyun Hong, Mi-Ra Choi, Yul-Lye Hwang, Jae Kyung Lee, Young-Joon Seo, Sooil Kim, Young-Ho Lee, Chang-Deok Kim, Jeung-Hoon Lee

    Hong DK, et al. Ann Dermatol. 2021 Aug;33(4):339-344. https://doi.org/10.5021/ad.2021.33.4.339


  • Effects of povidone‐iodine composite on the elimination of bacterial biofilm

    by Leonita Pinto Jeronimo, Mi‐Ra Choi, Sun Hee Yeon, Soo Kyoung Park, Young Hoon Yoon, Seung Hyeon Choi, Hwa‐Jung Kim, In‐Taek Jang, Jeong‐Kyu Park, Ki‐Sang Rha, et al.

    Background: Povidone‐iodine (PVP‐I) is well known as an antiseptic and exhibits extensive activity against various pathogens. However, due to its uniquely unpleasant nature, it cannot be used locally to deactivate various sinonasal pathogens. Therefore, we developed a PVP‐I composite that blocks the unpleasant odor of PVP‐I for use as a local antiseptic in the sinonasal cavity and evaluated its effect on bacterial biofilm's formation and elimination in in vivo and in vitro models.Methods: MTT, lactate dehydrogenase, and live/dead staining assay were performed to examine the cellular toxicity of PVP‐I composites on the primary human nasal epithelial and RPMI 2650 cells. Crystal violet assay was performed to quantify bacterial biofilm after treating with various agents, including PVP‐I and antibiotics. Hematoxylin‐and‐eosin staining, live/dead staining assay, and scanning electron microscopy were conducted to evaluate the effect of PVP‐I on biofilm formation in a mice biofilm model.Results: It was observed that the PVP‐I composite did not have any significant toxic effect on the nasal epithelial cells. Furthermore, the PVP‐I composite effectively inhibited the formation of bacterial biomass within a dose‐dependent manner after 48 hours of incubation with Pseudomonas aeruginosa and Staphylococcus aureus. In mice, it effectively eliminated biofilm from the mucosa of the nasal cavity and maxillary sinus at the tested concentrations.Conclusion: The results of this study indicate that the PVP‐I composite is a promising compound that could be used locally to prevent the formation of biofilms and to eliminate them from the sinonasal cavity.


  • Open Access

    Possible Role of Lysine Demethylase 2A in the Pathophysiology of Psoriasis

    by Dong Ha Kim, Mi-Ra Choi, Jae Kyung Lee, Dong-Kyun Hong, Kyung Eun Jung, Chong Won Choi, Young Lee, Chang-Deok Kim, Young-Joon Seo, Jeung-Hoon Lee

    Kim DH, et al. Ann Dermatol. 2020 Dec;32(6):481-486. https://doi.org/10.5021/ad.2020.32.6.481


  • Open Access

    Chloroquine Treatment Suppresses Mucosal Inflammation in a Mouse Model of Eosinophilic Chronic Rhinosinusitis

    by Mi-Ra Choi, Jun Xu, Seulgi Lee, Sun-Hee Yeon, Soo-Kyoung Park, Ki-Sang Rha, Yong Min Kim

    Choi MR, et al. Allergy Asthma Immunol Res. 2020 Nov;12(6):994-1011. https://doi.org/10.4168/aair.2020.12.6.994